

Web-Based STD Tool Makes Screening Accessible

BY BRUCE JANCIN

ESTES PARK, COLO. — The STD Wizard is a patient-friendly Internet tool for determining individual STD screening needs that is a particularly good fit for busy primary care medical practices.

"I would recommend this site to your patients," Dr. L. Chesney Thompson said at a conference on internal medicine sponsored by the University of Colorado.

The STD Wizard (www.stdwizard.org) involves a 5-minute online questionnaire in which patients answer simple multiple-choice questions about their demographics, history, location, and previous STD screening.

The Wizard is not a diagnostic tool; instead it analyzes an individual's answers and produces customized recommendations for STD screening. Patients are encouraged to print out the summary and

males—aren't screened at all for HPV. Herpes simplex virus isn't screened for or reported, either. And those are probably the two most common STDs; 80% of women in this country will have been exposed to HPV by age 50," he noted.

Five of the top 10 reportable diseases in the United States are STDs. Chlamydia is the most common, with roughly 3 million new cases a year. The CDC recommends annual screening for chlamy-

dia infection in all sexually active females aged 25 years or less and routine screening of older women with risk factors, such as new or multiple partners.

Routine screening isn't recommended for chlamydia in young men because there is insufficient evidence of benefit. But a low threshold for screening high-risk men is appropriate, Dr. Thompson said.

Similarly, although there are as yet no official guidelines for HPV anal screen-

ing in men who have sex with men, "there are compelling reasons for doing so," he continued.

When a patient is diagnosed with one STD, it's worthwhile to consider casting a broader net and screening for others, Dr. Thompson said. This might involve screening for the major reportable ones—gonorrhea, syphilis, chlamydia, chancroid, and HIV—along with hepatitis B and C and herpes simplex. ■



The STD Wizard involves a 5-minute online questionnaire with simple multiple-choice questions.

DR. THOMPSON

bring it to their physician for action, explained Dr. Thompson, chief of the section of general ob.gyn. at the university.

The STD Wizard's recommendations are based on the 2006 Sexually Transmitted Diseases Treatment Guidelines of the Centers for Disease Control and Prevention. The Wizard was developed and funded by the Medical Institute for Sexual Health and the CDC. The goal is to help rein in the nation's STD epidemic by reaching out to the public in a novel way to encourage greater use of guideline-recommended screening. The idea is to take the screening guidelines directly to the public in an accessible way.

By CDC estimates, 19 million new cases of STDs occur annually in the United States, nearly half in 15- to 24-year-olds. But that 19 million figure is "a woeful underestimate," Dr. Thompson said.

"Half of the population—that is,

CDC's 'Yellow Book' Is Online

The 2010 edition of the Centers for Disease Control and Prevention's "Yellow Book" on health information for international travelers is now available online (www.cdc.gov/travel) and in hard copy. The book, which always has a yellow cover, includes information on topics including jet lag, cruise ship travel, international adoptions, common respiratory conditions, drug-vaccine interactions, and travelers' diarrhea. Some topics such as medical tourism are appearing in this edition for the first time. For more information, contact Elsevier at 1-800-545-2522 or www.us.elsevierhealth.com. ■

Take on the mealtime challenge

And help your patients improve glycemic control with NovoLog®, the #1 selling rapid-acting mealtime insulin.¹

Model is for illustrative purposes only.

NovoLog® is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important safety information

NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients. NovoLog® has a more rapid onset and shorter duration of action than regular human insulin. An injection of NovoLog® should be immediately followed by a meal within 5 to 10 minutes. Because of the short duration of action of NovoLog®, a longer-acting insulin also should be used in patients with type 1 diabetes and may be needed in patients with type 2 diabetes. **When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent.** Hypoglycemia is the most common adverse effect of all insulin therapies, including NovoLog®. The timing of hypoglycemia usually reflects the time-action profile of the administered insulins.

Any change of insulin dose should be made cautiously and only under medical supervision. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity.

Severe, life-threatening generalized allergy, including anaphylactic reaction, may occur with any insulin product, including NovoLog®. Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus. Insulin, particularly when given intravenously or in settings of poor glycemic control, may cause hypokalemia. Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.

To access complimentary e-learning programs, visit novomedlink.com/NovoLog.



Please see brief summary of Prescribing Information on adjacent page.

FlexPen® and NovoLog® are registered trademarks of Novo Nordisk A/S.
© 2009 Novo Nordisk Inc. 137970

June 2009

